Dr James Paul Martin, MD MPH | |
520 Handeyside Lane, Suite 3, Fort Atkinson, WI 53558 | |
(920) 568-5018 | |
(920) 568-5018 |
Full Name | Dr James Paul Martin |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 520 Handeyside Lane, Fort Atkinson, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1881754992 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 37825020 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr James Paul Martin, MD MPH 520 Handeyside Lane, Suite 3, Fort Atkinson, WI 53558 Ph: (920) 568-5018 | Dr James Paul Martin, MD MPH 520 Handeyside Lane, Suite 3, Fort Atkinson, WI 53558 Ph: (920) 568-5018 |
News Archive
Although a class schedule with later start times allows colleges students to get more sleep, it also gives them more time to stay out drinking at night. As a result, their grades are more likely to suffer, suggests a research abstract that will be presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.
A study of volatile organic compounds (VOCs) in urine did not find an association between use of menstrual products and VOCs.
On the road to global economic recovery, the BRIC countries (Brazil, Russia, India and China) are setting up a new scene. Brazil, in particular, is the 9th economy in the world and is expected to reach the 8th position by 2012. New opportunities set a promising healthcare market perspective with a strong potential for further growth.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
› Verified 3 days ago